VBL Therapeutics Receives Milestone Payment

- February 8th, 2018

VBL Therapeutics (Nasdaq:VBLT) today announces that it has received a milestone payment from NanoCarrier, (TSE Mothers:4571) in relation to the license agreement for the development, commercialization, and supply of ofranergene obadenovec in Japan. As quoted in the press release: “We are excited about reaching this important milestone with NanoCarrier, and for the continuing development of our access … Continued

VBL Therapeutics (Nasdaq:VBLT) today announces that it has received a milestone payment from NanoCarrier, (TSE Mothers:4571) in relation to the license agreement for the development, commercialization, and supply of ofranergene obadenovec in Japan.

As quoted in the press release:

“We are excited about reaching this important milestone with NanoCarrier, and for the continuing development of our access to the Japanese market” said Dror Harats, M.D., chief executive officer of VBL Therapeutics. “Bringing this potentially life-changing new anticancer therapy to patients and physicians in Japan is important to all of us as we work to bring VB-111 to commercialization.”

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *